[{"address1": "117 Kendrick Street", "address2": "Suite 500", "city": "Needham", "state": "MA", "zip": "02494", "country": "United States", "phone": "781 292 4200", "website": "https://www.verastem.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.", "fullTimeEmployees": 73, "companyOfficers": [{"maxAge": 1, "name": "Mr. Daniel W. Paterson", "age": 62, "title": "President, CEO & Director", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 897590, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Calkins", "age": 35, "title": "CFO and Principal Accounting & Financial Officer", "yearBorn": 1988, "fiscalYear": 2023, "totalPay": 401833, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard H. Aldrich M.B.A.", "age": 69, "title": "Founder and Consultant", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 38387, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert A. Weinberg Ph.D.", "title": "Co-Founder & Chair of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Piyush B. Gupta Ph.D.", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michelle  Dipp M.D., Ph.D.", "age": 47, "title": "Co-Founder", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jonathan  Pachter Ph.D.", "age": 65, "title": "Chief Scientific Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 238176, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nate  Sanburn", "title": "Senior Vice President of Corporate Development & External Engagement", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cathy  Carew", "title": "Chief Organizational Effectiveness Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Crowther", "title": "Chief Commercial & Business Strategy Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 9, "compensationRisk": 6, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.44, "open": 2.43, "dayLow": 2.39, "dayHigh": 2.45, "regularMarketPreviousClose": 2.44, "regularMarketOpen": 2.43, "regularMarketDayLow": 2.39, "regularMarketDayHigh": 2.45, "beta": 0.154, "forwardPE": -1.0256411, "volume": 244369, "regularMarketVolume": 244369, "averageVolume": 650012, "averageVolume10days": 446420, "averageDailyVolume10Day": 446420, "bid": 2.39, "ask": 2.42, "bidSize": 300, "askSize": 500, "marketCap": 96584880, "fiftyTwoWeekLow": 2.1, "fiftyTwoWeekHigh": 14.22, "priceToSalesTrailing12Months": 9.658488, "fiftyDayAverage": 2.737, "twoHundredDayAverage": 7.8374, "currency": "USD", "enterpriseValue": 77846736, "floatShares": 40079551, "sharesOutstanding": 40243700, "sharesShort": 1968245, "sharesShortPriorMonth": 2266802, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.048899997, "heldPercentInsiders": 0.0092, "heldPercentInstitutions": 0.39838, "shortRatio": 2.98, "shortPercentOfFloat": 0.049099997, "bookValue": 0.701, "priceToBook": 3.4236808, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -89491000, "trailingEps": -3.21, "forwardEps": -2.34, "pegRatio": -0.44, "enterpriseToRevenue": 7.785, "enterpriseToEbitda": -0.788, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "VSTM", "underlyingSymbol": "VSTM", "shortName": "Verastem, Inc.", "longName": "Verastem, Inc.", "firstTradeDateEpochUtc": 1327674600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "beed18bc-04ae-39af-bc79-04e660295dcc", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.4, "targetHighPrice": 20.0, "targetLowPrice": 7.0, "targetMeanPrice": 12.14, "targetMedianPrice": 13.0, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 83371000, "totalCashPerShare": 2.072, "ebitda": -98762000, "totalDebt": 41864000, "quickRatio": 3.107, "currentRatio": 3.284, "totalRevenue": 10000000, "debtToEquity": 104.634, "revenuePerShare": 0.372, "returnOnAssets": -0.41505, "returnOnEquity": -1.09967, "freeCashflow": -62644124, "operatingCashflow": -102147000, "grossMargins": 1.0, "operatingMargins": -1.8277, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]